The initial diagnosis of cancer is usually based on taking a physical biopsy and then a skilled interpretation by a pathologist followed by tumor genome sequencing to generate informed treatment decisions.  Numerous genomic targets have been utilized as diagnostic markers for treatment with specific therapeutics. Indeed several anticancer therapies require…

Rosetta Genomics said today it has agreed to acquire CynoGen, which does business as PersonalizeDx, from Prelude, in a purchase that expands the buyer’s presence and product offerings in oncology diagnostics. The acquisition will also create a combined pipeline for Rosetta Genomics that is set to introduce to market five…

There are huge benefits to genomic tumor assessment, both for better treatment now, and later, if first-line treatments fail. But I don’t think many cancer patients—and even some physicians—fully understand how important tumor sequencing can be to successful cancer treatment. Yet. This is not surprising. Outside of a few tests…